NeuroDerm to Host Investor Day on April 21, 2017
10 Avril 2017 - 1:00PM
NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical
company developing drug-device combinations for central nervous
system (CNS) disorders, today announced that the Company will host
its first Investor Day, taking place in New York on Friday, April
21, 2017.
Members of NeuroDerm’s executive team will be
joined by key opinion leaders to review the company’s clinical
programs for treating patients with moderate and severe Parkinson’s
disease addressing deficiencies of current treatments, to discuss
continuous levodopa administration and its potential to delay motor
complications and present the company's future development
plans.
Individuals can access the webcast in the Events
and Presentations section of the Investor Relations page at
NeuroDerm.com. The webcast will be archived on the
website.
Event
Date: April 21, 2017
Time: 10:30 a.m. – 1:30 p.m. ET (Registration
beginning at 10:00 a.m.)
Location: New York, New York
Speakers
• Robert Hauser, MD • Professor of Neurology,
Molecular Pharmacology and Physiology & Director, USF Health
Byrd Parkinson’s Disease and Movement Disorders Center• Karl
Kieburtz, MD, MPH • President, Clintrex, Robert Joynt
Professor of Neurology at the University of Rochester• Oded
Lieberman, PhD, Chief Executive Officer, NeuroDerm• Sheila Oren,
MD, Chief Medical Officer, NeuroDerm
Analysts and institutional investors seeking
more information about this event should contact Matt Ventimigila -
MVentimiglia@lazarpartners.com or by phone at 212-599-1265.
About
NeuroDerm
NeuroDerm is a clinical-stage pharmaceutical company developing
drug-device combinations for central nervous system (CNS) disorders
that are designed to overcome major deficiencies of current
treatments and achieve enhanced clinical efficacy through
continuous, controlled administration. NeuroDerm has three product
candidates in different stages of development which offer a
solution for almost every Parkinson’s disease patient from the
moderate to the very severe stage of the disease. NeuroDerm has
developed a line of levodopa and carbidopa (LD/CD) product
candidates administered through small belt pumps that deliver a
continuous, controlled dose of LD/CD. The LD/CD product candidates
are ND0612L and ND0612H, which are used for treatment of moderate
and advanced Parkinson’s disease patients, respectively, and which
are delivered subcutaneously. In addition, NeuroDerm is developing
ND0701, a novel subcutaneously delivered apomorphine formulation
for patients who suffer from moderate to severe Parkinson’s disease
and who do not respond well to LD/CD. NeuroDerm is headquartered in
the Weizmann Science Park in Rehovot, Israel.
NeuroDerm Contact:Oded S.
Lieberman, PhD, CEOoded@neuroderm.comTel.: +972-8-946 2729 Cell:
+1-617-517 6077
U.S. Investor Contact:David
CareyLazar Partners Ltd.dcarey@lazarpartners.com+212-867-1768
NEURODERM LTD. (NASDAQ:NDRM)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
NEURODERM LTD. (NASDAQ:NDRM)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024